Quantcast
Last updated on April 19, 2014 at 7:35 EDT

Latest Vagus nerve stimulation Stories

2013-04-04 08:29:36

HOUSTON, April 4, 2013 /PRNewswire/ -- Cyberonics, Inc. (NASDAQ:CYBX) today provided an update on its recent submission to the Centers for Medicare & Medicaid Services ("CMS") seeking reimbursement coverage for the treatment-resistant depression ("TRD") indication for the VNS Therapy(®) System. As previously announced, the company submitted a request to CMS for reconsideration of coverage for VNS Therapy for TRD and expected to receive a formal acknowledgment from CMS accepting or...

2013-03-25 12:27:11

DUBLIN, March 25, 2013 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/t8zp6f/neuromodulation) has announced the addition of the "Neuromodulation Market - [Spinal Cord Stimulation (SCS), Vagus Nerve Stimulation (VNS), Gastric Electrical Stimulation (GES), Deep Brain Stimulation (DBS), Sacral Nerve Stimulation (SNS), & Transcranial Magnetic Stimulation (TMS)] - Forecasts to 2017" report to their offering. (Logo:...

2013-02-22 23:01:23

Research and Markets announces the addition of "Neuromodulation Market — [Spinal Cord Stimulation (SCS), Vagus Nerve Stimulation (VNS), Gastric Electrical Stimulation (GES), Deep Brain Stimulation (DBS), Sacral Nerve Stimulation (SNS), & Transcranial Magnetic Stimulation (TMS)] — Forecasts to 2017" to its catalogue. (PRWEB) February 22, 2013 Neuromodulation devices have emerged as one of the fastest growing segments of the medical device market due to high demand for...

2013-02-19 08:34:05

MORRIS PLAINS, N.J., Feb. 19, 2013 /PRNewswire/ -- ElectroCore(®), a company dedicated to developing effective, non-invasive Vagal Nerve Stimulation (nVNS) therapies for serious medical conditions including primary headaches, announced today that its GammaCore(®) therapy has been approved for commercial sale by the Therapeutic Goods Administration in Australia and the National Institute of Surveillance of Medicine and Foods in the Ministry of Health in Colombia. GammaCore's...

2013-02-13 08:28:47

HOUSTON, Feb. 13, 2013 /PRNewswire/ -- Cyberonics, Inc. (NASDAQ:CYBX), a global leader in medical devices for the treatment and management of epilepsy, today announced it will participate in the following conferences. Dan Moore, Cyberonics' President & Chief Executive Officer, will participate in the neuromodulation panel discussion at the Citi 2013 Global Healthcare Conference in New York on Wednesday, February 27, 2013 at 11:05 AM Eastern Time. This panel discussion will not be...

2013-02-06 08:27:16

HOUSTON, Texas, Feb. 6, 2013 /PRNewswire/ -- Cyberonics, Inc. (NASDAQ: CYBX) today announced that the company will report financial results for the third quarter ended January 25, 2013, of its fiscal year ending April 26, 2013, on Friday, February 22, 2013, before regular market trading hours. The company will conduct a conference call to discuss those results on the same day at 8:00 AM Central Time (9:00 AM Eastern Time). Fiscal Year 2013 Third Quarter Results Webcast and Conference Call...

2013-02-04 12:25:52

HOUSTON, Feb. 4, 2013 /PRNewswire/ -- Cyberonics, Inc. (NASDAQ:CYBX) today announced that the lawsuit filed by former employee Andrew Hagerty in federal district court in Massachusetts was voluntarily dismissed without prejudice by Mr. Hagerty on February 1, 2013. The company has asserted that, under the terms of his employment, Mr. Hagerty's claims are subject to binding arbitration. Mr. Hagerty has the right to re-file the lawsuit or to pursue a resolution through binding...

2013-01-28 23:01:06

[193 Pages Report] Neuromodulation devices market report categorizes the global market of Spinal Cord Stimulation, Vagus Nerve Stimulation, Deep Brain Stimulation, Sacral Nerve Stimulation & Trans-cranial Magnetic Stimulation by procedure, technology, and application. (PRWEB) January 28, 2013 The “Neuromodulation Market — [Spinal Cord Stimulation, Vagus Nerve Stimulation, Gastric Electrical Stimulation, Deep Brain Stimulation, Sacral Nerve Stimulation & Trans-cranial...

2013-01-14 02:29:16

DALLAS, January 14, 2013 /PRNewswire/ -- The "Neuromodulation Market - [Spinal Cord Stimulation (SCS), Vagus Nerve Stimulation (VNS), Gastric Electrical Stimulation (GES), Deep Brain Stimulation (DBS), Sacral Nerve Stimulation (SNS) & Transcranial Magnetic Stimulation (TMS)] - Forecasts to 2017" analyzes and studies the major market drivers, restraints, and opportunities in North America, Europe, APAC, and Rest of the World. Browse market 93 data tables, 4 figures...

2013-01-10 08:25:59

MORRIS PLAINS, N.J., Jan. 10, 2013 /PRNewswire/ -- ElectroCore®, a company dedicated to developing effective, non-invasive Vagal Nerve Stimulation (nVNS) therapies for serious medical conditions including primary headaches, announced today that initial enrollment has begun for its FDA approved chronic migraine prevention study using its GammaCore nVNS therapy. The randomized, sham-controlled study is enrolling patients at 10 sites across the U.S. The study, which is expected to offer an...